Rouzioux C - Search Results

1

Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.

Delaugerre C, Flandre P, Chaix ML, Ghosn J, Raffi F, Dellamonica P, Jaeger H, Shürmann D, Cohen-Codar I, Van PN, Norton M, Taburet AM, Delfraissy JF, Rouzioux C; MONARK Study Group. Delaugerre C, et al. Among authors: rouzioux c. Antimicrob Agents Chemother. 2009 Jul;53(7):2934-9. doi: 10.1128/AAC.01643-08. Epub 2009 May 18. Antimicrob Agents Chemother. 2009. PMID: 19451297 Free PMC article. Clinical Trial.

2

Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.

Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP. Delfraissy JF, et al. Among authors: rouzioux c. AIDS. 2008 Jan 30;22(3):385-93. doi: 10.1097/QAD.0b013e3282f3f16d. AIDS. 2008. PMID: 18195565 Clinical Trial.

3

Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.

Ghosn J, Chaix ML, Peytavin G, Bresson JL, Galimand J, Girard PM, Raffi F, Cohen-Codar I, Delfraissy JF, Rouzioux C. Ghosn J, et al. Among authors: rouzioux c. J Antimicrob Chemother. 2008 Jun;61(6):1344-7. doi: 10.1093/jac/dkn098. Epub 2008 Mar 13. J Antimicrob Chemother. 2008. PMID: 18343806 Clinical Trial.

4

Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone.

Flandre P, Delaugerre C, Ghosn J, Chaix ML, Horban A, Girard PM, Gladysz A, Cohen-Codar I, Van PN, Taburet AM, Rouzioux C, Delfraissy JF; MONARK Study Group. Flandre P, et al. Among authors: rouzioux c. Antivir Ther. 2009;14(1):93-7. Antivir Ther. 2009. PMID: 19320241 Clinical Trial.

5

Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial.

Avettand-Fenoel V, Flandre P, Chaix ML, Ghosn J, Delaugerre C, Raffi F, Ngovan P, Cohen-Codar I, Delfraissy JF, Rouzioux C; MONARK Study Group. Avettand-Fenoel V, et al. Among authors: rouzioux c. J Antimicrob Chemother. 2010 May;65(5):1005-7. doi: 10.1093/jac/dkq084. Epub 2010 Mar 18. J Antimicrob Chemother. 2010. PMID: 20299496 Clinical Trial.

6

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.

Ghosn J, Delaugerre C, Flandre P, Galimand J, Cohen-Codar I, Raffi F, Delfraissy JF, Rouzioux C, Chaix ML. Ghosn J, et al. Among authors: rouzioux c. PLoS One. 2011;6(9):e24798. doi: 10.1371/journal.pone.0024798. Epub 2011 Sep 20. PLoS One. 2011. PMID: 21949754 Free PMC article.

7

Residual HIV-1 replication may impact immune recovery in patients on first-line lopinavir/ritonavir monotherapy.

Tran TA, Ghosn J, Avettand-Fenoël V, Hendel-Chavez H, de Goër de Herve MG, Cohen-Codar I, Rouzioux C, Delfraissy JF, Taoufik Y. Tran TA, et al. Among authors: rouzioux c. J Antimicrob Chemother. 2015 Sep;70(9):2627-31. doi: 10.1093/jac/dkv138. Epub 2015 May 28. J Antimicrob Chemother. 2015. PMID: 26023212 Clinical Trial.

8

Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir.

Delaugerre C, Teglas JP, Treluyer JM, Vaz P, Jullien V, Veber F, Rouzioux C, Chaix ML, Blanche S. Delaugerre C, et al. Among authors: rouzioux c. J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1269-75. doi: 10.1097/01.qai.0000137408.78031.37. J Acquir Immune Defic Syndr. 2004. PMID: 15385734

9

High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study.

Frange P, Galimand J, Goujard C, Deveau C, Ghosn J, Rouzioux C, Meyer L, Chaix ML. Frange P, et al. Among authors: rouzioux c. J Antimicrob Chemother. 2009 Jul;64(1):135-41. doi: 10.1093/jac/dkp151. Epub 2009 May 2. J Antimicrob Chemother. 2009. PMID: 19411680

10

Despite being highly diverse, immunovirological status strongly correlates with clinical symptoms during primary HIV-1 infection: a cross-sectional study based on 674 patients enrolled in the ANRS CO 06 PRIMO cohort.

Ghosn J, Deveau C, Chaix ML, Goujard C, Galimand J, Zitoun Y, Allègre T, Delfraissy JF, Meyer L, Rouzioux C; ANRS PRIMO Cohort. Ghosn J, et al. Among authors: rouzioux c. J Antimicrob Chemother. 2010 Apr;65(4):741-8. doi: 10.1093/jac/dkq035. Epub 2010 Feb 18. J Antimicrob Chemother. 2010. PMID: 20167586

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

511 results

Search Page

Filters